Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Leon, P. (Pedro) | - |
dc.creator | Jimenez, M. (Miguel) | - |
dc.creator | Barona, P. (Pascual) | - |
dc.creator | Sierrasesumaga, L. (Luis) | - |
dc.date.accessioned | 2012-11-22T15:13:39Z | - |
dc.date.available | 2012-11-22T15:13:39Z | - |
dc.date.issued | 1998 | - |
dc.identifier.citation | León P, Jiménez M, Barona P, Sierrasesúmaga L. Recombinant human erythropoietin for the treatment of anemia in children with solid malignant tumors. Med Pediatr Oncol. 1998 Feb;30(2):110-6. | es_ES |
dc.identifier.issn | 0098-1532 | - |
dc.identifier.uri | https://hdl.handle.net/10171/23773 | - |
dc.description.abstract | Cancer is often associated with chronic anemia which frequently requires blood transfusions. This study was performed to assess the efficacy and safety of r-HuEPO therapy in children with cancer. PATIENTS AND METHODS: Twenty-five patients under 18 years of age with solid malignant tumors were treated with 150 U/kg/day of r-HuEPO 5 times weekly for 12 weeks. Response was defined as an increase of the baseline hemoglobin level by at least 2 g/dl. r-HuEPO patients were compared to 25 matched historical controls. RESULTS: Response was achieved in 72% of r-HuEPO patients. Hemoglobin level increased from 9.8 +/- 0.6 g/dl at baseline to 12.4 +/- 1.7 g/dl at the end of treatment in the r-HuEPO group and increased from 9.5 +/- 0.7 g/dl to 9.6 +/- 1.4 g/dl in the control group (P < .001, Student's t-test). Only 16% of patients receiving r-HuEPO required blood transfusions vs 96% of control patients (P < .001, Student's t-test), with mean units of blood transfused per patient being 0.35 in the r-HuEPO group and 3.56 in controls (P < .001, Student's t-test). There was a statistically significance improvement in Karnofsky's index in r-HuEPO patients. No adverse reaction related to r-HuEPO therapy was observed. CONCLUSIONS: r-HuEPO is a safe and effective means of increasing hemoglobin level and reducing blood requirements in children with solid malignant tumors receiving chemotherapy. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Wiley-Blackwell | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.subject | Neoplasms/complications/therapy | es_ES |
dc.subject | Recombinant Proteins | es_ES |
dc.subject | Hemoglobins/analysis | es_ES |
dc.title | Recombinant Human Erythropoietin for the Treatment of Anemia in Children With Solid Malignant Tumors | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.relation.publisherversion | http://onlinelibrary.wiley.com/doi/10.1002/(SICI)1096-911X(199802)30:2%3C110::AID-MPO8%3E3.0.CO;2-L/pdf | es_ES |
dc.type.driver | info:eu-repo/semantics/article | es_ES |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.